Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Refining the Toxicity Profile of Crizotinib

Refining the Toxicity Profile of Crizotinib EDITORIAL Benjamin Solomon, MBBS, PhD, FRACP rizotinib (Xalkori) is an orally available, small molecule inhibitor of the ALK, ROS1 Cand c-MET tyrosine kinases. It is standard of care for the management of ALK-positive 1,2 3 non-small cell lung cancer (NSCLC) and has activity in ROS1 rearranged NSCLC and c-MET amplified NSCLC. Accelerated approval of crizotinib by the U.S. Food and Drug Administration was granted in August 2011 for the treatment of advanced ALK-positive NSCLC on basis of a phase I and phase II trial, with initial data from 255 patients. Since then, crizotinib has been approved in approximately 78 countries and received by thousands of ALK-positive NSCLC patients worldwide. Data from the initial clinical trials with crizotinib indicated that it was effective, safe, XXX and generally well tolerated. In the phases 1, 2, and 3 studies of crizotinib, the most often reported adverse events were visual changes, nausea, diarrhea, vomiting, edema, constipa- 1,2,5,6 tion, and elevated transaminases. The most serious toxicities were hepatotoxicity and 1,2,5,6 pneumonitis. As one would expect, with increasing clinical experience with crizotinib over recent years other toxicities have been described including asymptomatic bradycar- 7 6 dia and decreased total testosterone in males. In this issue http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Refining the Toxicity Profile of Crizotinib

Solomon, Benjamin
Journal of Thoracic Oncology , Volume 9 (11) – Nov 1, 2014
Download PDF
2 pages

Loading next page...
 
/lp/wolters-kluwer-health/refining-the-toxicity-profile-of-crizotinib-VqF63vjHYe

References (14)

Copyright
Copyright © 2014 by the International Association for the Study of Lung Cancer
ISSN
1556-0864
DOI
10.1097/JTO.0000000000000375
pmid
25436794
Publisher site
See Article on Publisher Site

Abstract

EDITORIAL Benjamin Solomon, MBBS, PhD, FRACP rizotinib (Xalkori) is an orally available, small molecule inhibitor of the ALK, ROS1 Cand c-MET tyrosine kinases. It is standard of care for the management of ALK-positive 1,2 3 non-small cell lung cancer (NSCLC) and has activity in ROS1 rearranged NSCLC and c-MET amplified NSCLC. Accelerated approval of crizotinib by the U.S. Food and Drug Administration was granted in August 2011 for the treatment of advanced ALK-positive NSCLC on basis of a phase I and phase II trial, with initial data from 255 patients. Since then, crizotinib has been approved in approximately 78 countries and received by thousands of ALK-positive NSCLC patients worldwide. Data from the initial clinical trials with crizotinib indicated that it was effective, safe, XXX and generally well tolerated. In the phases 1, 2, and 3 studies of crizotinib, the most often reported adverse events were visual changes, nausea, diarrhea, vomiting, edema, constipa- 1,2,5,6 tion, and elevated transaminases. The most serious toxicities were hepatotoxicity and 1,2,5,6 pneumonitis. As one would expect, with increasing clinical experience with crizotinib over recent years other toxicities have been described including asymptomatic bradycar- 7 6 dia and decreased total testosterone in males. In this issue

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Nov 1, 2014

There are no references for this article.